Overview

This register measures the safety and effectiveness of biologic and biosimilar treatment for juvenile idiopathic arthritis (JIA).

BSR and Versus Arthritis are partnering to secure the long-term future of our patient studies on children and young people with JIA.

The BSR Etanercept and Versus Arthritis Biologics for Children with Rheumatic Diseases studies have merged into the UK JIA Biologics Register.

Funding has been extended for at least four more years; the University of Manchester continues to manage the study.

Learn more about the register

Access the UK JIA Biologics Register site

Find out more